The entitlement issue closes tomorrow so if you were selling to...

The entitlement issue closes tomorrow so if you were selling to fund the take up of your entitlement then yesterday was the last day to do so if you wanted a clean transfer of funds without committing any additional dollars.

I would be very encouraged by a full take up of rights from a combination of existing shareholders plus Baker Young clients.

I'm sure we will see in the quarterly how dire the cash situation is with the R&D tax refund largely going to Berlin Pharma (the gift that keeps on taking).

But looking forwards and not backwards will see the company with close to $4m in the bank with key value adding milestones such as Zolpimist approval and an Anagrelide update not too far away.

Not to mention whatever else is simmering in the background.